OTCMKTS:RGIN Regenicin (RGIN) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisChartSEC Filings About Regenicin Stock (OTCMKTS:RGIN) Get Regenicin alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket Capitalization$20 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Regenicin, Inc. is a biotechnology company focused on regenerative medicine and tissue-engineering technologies. The company has concentrated on developing products intended to help repair or replace damaged human tissue, particularly skin. Its principal product candidate has been PermaDerm™, a tissue-engineered skin substitute designed for applications including the treatment of severe burns and other serious skin wounds. The technology is intended to support the regeneration of functional skin and address situations in which conventional wound-care methods may be insufficient. Regenicin was formerly known as Entest Group, Inc. before adopting its current name. Publicly available information provides limited detail about the company’s current leadership, commercial operations, and geographic markets served.AI Generated. May Contain Errors. Read More Receive RGIN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Regenicin and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RGIN Stock News HeadlinesRegenicin Inc.July 15, 2026 | barrons.comMade Scientific and Regenicin Announce Manufacturing Relationship to Advance NovaDerm Toward FDA Product ApprovalApril 23, 2026 | marketwatch.comALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.October 15 at 1:00 AM | Weiss Ratings (Ad)HistoryOctober 20, 2024 | npr.orgNRegenicin, Inc. (RGIN)September 5, 2024 | finance.yahoo.comLGBT+ History Month - Teaching ResourcesMay 3, 2024 | bbc.co.ukJohn Kerry praises Biden for preventing 'uncontrolled war in many regions'January 19, 2024 | foxnews.comHistory of Walmart: Timeline and FactsDecember 9, 2023 | thestreet.comSee More Headlines RGIN Stock Analysis - Frequently Asked Questions How were Regenicin's earnings last quarter? Regenicin Inc. (OTCMKTS:RGIN) issued its quarterly earnings results on Wednesday, August, 19th. The company reported $0.00 EPS for the quarter. Company Calendar Last Earnings8/19/2020Today10/15/2026Fiscal Year End9/30/2027Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolOTCMKTS:RGIN CIK1412659 Webwww.regenicin.com Phone(732) 757-5500FaxN/AEmployees3Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares165,770,000Free FloatN/AMarket Cap$20 thousand OptionableNot Optionable BetaN/A The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (OTCMKTS:RGIN) was last updated on 10/13/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored100% overnight gains?Rumors are circulating that Elon Musk is preparing to acquire three publicly traded companies. Dr. Mark Sko...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Regenicin Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Regenicin With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
